Severe pulmonary hypertension: Data from the Swiss Registry

Swiss Medical Weekly

Volumn 131, Issue 23-24, 2001, Pages 346-350

  Stricker, H ^a   Domenighetti, G ^a   Popov, W ^a   Speich, R ^a   Nicod, L ^a   Aubert, J D ^a   Soler M ^a  

^a Regional Hospital   (Switzerland)

Author keywords

Aetiology; Prognosis; Pulmonary hypertension; Registry

Indexed keywords

CALCIUM ANTAGONIST; ILOPROST; PROSTANOID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLLAGEN DISEASE; DATA BASE; DEATH; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG EMBOLISM; LUNG TRANSPLANTATION; MALE; OXYGEN SATURATION; PARAMETER; PATIENT CODING; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; REGISTER; RETROSPECTIVE STUDY; SURVIVAL; SWITZERLAND; THROMBOEMBOLISM; UNIVERSITY HOSPITAL; WALKING;

EID: 0035897828     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization
2. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
3. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension
4. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
5. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
6. ACCP consensus statement: Primary pulmonary hypertension
7. Aminorex and pulmonary hypertension. A review
8. Primary pulmonary hypertension: Insights into pathogenesis from epidemiology
9. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
10. Mortality from primary pulmonary hypertension in the United States, 1979-1996
11. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
12. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study
13. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension
14. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
15. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
16. Severe pulmonary hypertensive diseases: A perspective
17. Primary pulmonary hypertension
18. Pulmonary vascular diseases
19. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension